Kangmei Pharmaceutical Co Ltd

Kangmei Pharmaceutical maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.15, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.26, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. Free cash flow is modest at 17.25 million CNY, while operating cash flow stands at 111.35 million CNY, indicating some capacity to fund operations and reinvestment.

Profitability metrics for Kangmei Pharmaceutical are weak, with a return on equity (ROE) of 0.14% and a return on assets (ROA) of 0.08%, both significantly below the industry median for pharmaceutical firms. The company reported a net income of 10.33 million CNY, despite a gross profit of 948.18 million CNY, highlighting inefficiencies in operating expenses and cost management.

Geographically, Kangmei Pharmaceutical is heavily concentrated in the Chinese market, with no disclosed international revenue streams. Segment-wise, the company operates as a single business unit, with no material diversification across product lines or therapeutic areas. This lack of diversification increases exposure to domestic regulatory and economic shifts.

The company's growth trajectory is mixed. While revenue for the latest period was 5.25 billion CNY, the operating income was negative at -12.77 million CNY, indicating a decline in profitability. The outlook for the current fiscal year suggests continued pressure on margins, with no clear path to restoring positive operating income.

Risk factors for Kangmei Pharmaceutical include medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations or pursue growth opportunities. Additionally, the company's ESG scores are low, with a social pillar score of 24.53 and a governance pillar score of 27.35, indicating potential reputational and governance risks.

Recent events include a reported EPS of -0.93 CNY, reflecting a challenging earnings performance. The company has not disclosed any major capital-raising activities or strategic acquisitions in the latest filings, suggesting a focus on cost control and operational efficiency.